Immunogenic Structural Features of a Breast Tumor-Specific Epitope for Cancer Immunotherapy.
Abstract
The objectives of the research program are to understand the structure-immunogenicity relationships of tumor-specific mucin common to human breast adenocarcinomas, and the regulation of tumor-specific lymphoid cells that respond to the tumor-specific immunogen. Using the synthetic native MUC1 peptide PDTRPAPGSTAPPAHGVTSA and the mutated T3-N3 MUC1 (containing the mutation in the TSE) these relationships are being studied. The peptides were equal in immunogenicity with respect to cell proliferation and tumor-specific cytotoxicity. Both peptides also induced expansion of a narrow T cell population, each with a unique VB repefloire. The conformation of each peptide is being evaluated H-NMR. Amino acids and carbohydrates found in the MUC1 molecule have been characterized by x-ray photoelectron spectroscopy. This method is also able to detect the point mutation within the TSE. Thus, we can design, construct and characterize the biophysical properties of immunogenic mucin peptides which can elicit tumor-specific responses. This progress in understanding of the structure-immunogenicity relationships of tumor-specific immunogens, and the regulation of the lymphoid cells responding to the immunogen, should maximize the use of synthetic peptide immunogens for the adoptive immunotherapy of adenocarcinomas and as a potential vaccine.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 1995
- Accession Number
- ADA302125
Entities
People
- Kenneth E. Dombrowski
- Stephen E. Wright